Abstract
Introduction

Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD) is a rare but lethal complication in the setting of allogeneic hematopoietic stem cell transplantation (HSCT) (1). The overall cumulative incidence of EBV-LPD is low, occurring in approximately 1-3% of allogeneic HSCT, and most patients receive the diagnosis within the initial 6 months after transplantation. The major risk factor for EBV-LPD is the use of in vivo T-cell depletion with antithymocyte globulin (ATG) for prophylaxis of acute graftversus-host disease (GVHD), or reduced intensity conditioning regimens (2, 3). EBV-LPD caused by the outgrowth of latently infected B cells under the absence of competent immune surveillance systems as a consequence of ATG treatment. Because of the rapid clinical course of EBV-LPD, immediate treatment is crucial to reduce mortality
 (4, 5 
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copies/μg DNA) and pathological examination from bone marrow aspiration (demonstrating an increase in CD20 positive lymphocytes positive for EBV-encoded mRNA (EBER) by in situ hybridization (
) confirmed the diagnosis of EBV-LPD. After the single administration of rituximab, the EBV-LPD stabilized with a low EBV-DNA load of 100 copies/μg DNA level, as shown in
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10,000,000 1,000,000 10,0000 (2, 6, 11) , although other reports have described different threshold values (Table 1) (7, (12) (13) (14) . 
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